The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | Real world data: CAR T-cell therapy for hematological cancers
In this video, Duane Schulthess, BA, from Vital Transformation, Flanders, Belgium, discusses the current real world data for patients treated with CAR T-cell therapy. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Mr Schulthess discusses the differences in prescription practice and health economics observed in the real world. He also highlights the limitations of the existing health data for CAR T-cell therapy and stresses the need for overcoming them in order for the therapy to become more widely available. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
